March 12, 2020
•Study to Look at DNA, mRNA and miRNA
•IRB Approved Clinical Study
•Seeks to identify Inflammation Indicators
DELRAY BEACH – Designer Genomics International, a Contract Research Organization (CRO) announced today that it has selected Genetics Institute of America as the Institutional Review Board approved testing laboratory for a new clinical study into inflammasome activation.
“My long experience with the management team of the laboratory made them the logical choice as genomics laboratory,” said Marvin Hausman, MD, the study principal investigator at Designer Genomics International.
“Our experience in working with DNA and RNA as well as our collaborative relationship with ThermoFischer Scientific make for a great combination for this study,” said Holly Magliochetti, CEO of Genetics Institute of America.
Genetics Institute of America will be running DNA, RNA, mRNA and miRNA studies on buccal swab specimens. The study of currently available cancer genomic and pharmacogenomic DNA profiles combined with newly designed proprietary mRNA and miRNA panels will allow leveraging newly developed machine learning and deep learning methods for genetic analysis. The study (GH-101 Genetic Susceptibility to Chronic Disease) is designed to identify differentially expressed genes (DEGs) associated with development of chronic diseases such as Cardiovascular Disease, End Stage Renal Disease, PTSD, as well as Cancer.